Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,494 active trials253 approved drugs3,567 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,594 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05786924 | Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies | recruiting | Phase 1 / Phase 2 | 554 | Institut de Recherches Internationales ServierOTHER | 10 | Sep 16, 2026 | clinicaltrials |
| NCT05807932 | Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML | recruiting | Phase 1 / Phase 2 | 38 | Heinrich-Heine University, DuesseldorfOTHER | 1 |
| Sep 16, 2026 |
| clinicaltrials |
| NCT05892393 | Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma | recruiting | Phase 1 | 20 | Robert Flavell, MD, PhDOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06096038 | Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC | recruiting | Phase 1 | 33 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06345027 | Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)(CASEY) | recruiting | Phase 1 | 78 | Baylor College of MedicineOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06427941 | A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 630 | BeOne MedicinesINDUSTRY | 9 | Sep 16, 2026 | clinicaltrials |
| NCT06735664 | Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation | recruiting | Phase 1 | 23 | City of Hope Medical CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06843967 | A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma | recruiting | Phase 1 / Phase 2 | 54 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06873555 | A Study of DC05F01 in Chinese Patients With Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 60 | Heronova PharmaceuticalsINDUSTRY | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07080242 | Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors | recruiting | Phase 1 | 120 | SystImmune Inc.INDUSTRY | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07181941 | Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 30 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07213609 | A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors | recruiting | Phase 1 / Phase 2 | 47 | GlaxoSmithKlineINDUSTRY | 9 | Sep 16, 2026 | clinicaltrials |
| NCT07332455 | First-Time-in-Human Study of GSK5471713 in Adults With mCRPC | recruiting | Phase 1 / Phase 2 | 54 | GlaxoSmithKlineINDUSTRY | 8 | Sep 16, 2026 | clinicaltrials |
| NCT07343934 | huCART19-IL18-eDHFR Cells in Relapsed/Refractory Follicular Lymphoma | recruiting | Phase 1 | 6 | University of PennsylvaniaOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07489287 | GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer | recruiting | Phase 1 | 18 | Roswell Park Cancer InstituteOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07532902 | A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer | recruiting | Phase 1 | 60 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07619339 | A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer | recruiting | Phase 1 | 16 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04585750 | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | recruiting | Phase 1 / Phase 2 | 300 | PMV Pharmaceuticals, IncINDUSTRY | 9 | Sep 15, 2026 | clinicaltrials |
| NCT04780568 | Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer | recruiting | Phase 1 | 25 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT04969315 | TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma | recruiting | Phase 1 / Phase 2 | 35 | Portage BiotechINDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05438459 | GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant Ascites | recruiting | Phase 1 / Phase 2 | 176 | Kyushu UniversityOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05554939 | Allogenic CD19-targeting CAR-γδT Cell Therapy in R/R NHL | recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05607095 | A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma | recruiting | Phase 1 | 40 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05739981 | Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer(MRD) | recruiting | Phase 1 / Phase 2 | 30 | ImunonINDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05798897 | Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma(APOLLO) | recruiting | Phase 1 | 79 | Marker Therapeutics, Inc.INDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06132438 | Immunotherapy Targeting of Cytomegalovirus Antigens in Glioblastoma | recruiting | Phase 1 | 26 | Charlotte LemechOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06357377 | A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors | recruiting | Phase 1 | 12 | Neonc Technologies, Inc.INDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06466395 | A Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated Leukemias | recruiting | Phase 1 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06810583 | A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia | recruiting | Phase 1 | 29 | St. Jude Children's Research HospitalOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07165132 | Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs. | recruiting | Phase 1 | 104 | RayzeBio, Inc.INDUSTRY | 2 | Sep 15, 2026 | clinicaltrials |
| NCT07195916 | A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies | recruiting | Phase 1 | 280 | Incyte CorporationINDUSTRY | 5 | Sep 15, 2026 | clinicaltrials |
| NCT07217171 | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas | recruiting | Phase 1 | 160 | EvolveImmune United, IncINDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07341737 | SL-28 for Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 60 | Second Life TherapeuticsINDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07367516 | Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer | recruiting | Phase 1 / Phase 2 | 105 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07493512 | Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer | recruiting | Phase 1 | 40 | AmgenINDUSTRY | 2 | Sep 15, 2026 | clinicaltrials |
| NCT07581184 | A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer(BActinium-1) | recruiting | Phase 1 | 138 | Aktis Oncology, Inc.INDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07620275 | Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA | recruiting | Phase 1 | 9 | Chinese PLA General HospitalOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07655583 | OBSERVE: A Pilot Study Of Omission Of Brain Metastasis Stereotactic Radiosurgery Following Resection With CNS-Active Systemic Therapy | recruiting | Phase 1 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07723703 | Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML(BRAMLIE) | recruiting | Phase 1 | 54 | Amphista Therapeutics LtdINDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT03471260 | Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies | recruiting | Phase 1 / Phase 2 | 96 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04380545 | Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer | recruiting | Phase 1 / Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04544592 | UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL | recruiting | Phase 1 / Phase 2 | 45 | University of Colorado, DenverOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04771130 | A Study of BGB-11417 in Participants With Myeloid Malignancies | recruiting | Phase 1 / Phase 2 | 260 | BeOne MedicinesINDUSTRY | 10 | Sep 14, 2026 | clinicaltrials |
| NCT04977453 | GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 317 | GI Innovation, Inc.INDUSTRY | 2 | Sep 14, 2026 | clinicaltrials |
| NCT04993690 | A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma | recruiting | Phase 1 | 200 | Guangzhou Lupeng Pharmaceutical Company LTD.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05698524 | A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma | recruiting | Phase 1 | 24 | University of NebraskaOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06090539 | A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas | recruiting | Phase 1 / Phase 2 | 460 | Bristol-Myers SquibbINDUSTRY | 15 | Sep 14, 2026 | clinicaltrials |
| NCT06134960 | NKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumor | recruiting | Phase 1 | 12 | Peking UniversityOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06137144 | AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.(PRIMAVERA) | recruiting | Phase 1 / Phase 2 | 161 | AstraZenecaINDUSTRY | 11 | Sep 14, 2026 | clinicaltrials |
| NCT06246968 | A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer | recruiting | Phase 1 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
Data updated 15 days agoSource updated Sep 16, 2026source: clinicaltrials